|| Checking for direct PDF access through Ovid
Anticancer agent-incorporating polymeric micelles accumulate effectively in tumors via the enhanced permeability and retention effect to exert potent antitumor effects. However, combined use of such micelles has not been elucidated. We compared the effect of combining the epirubicin-incorporating micelle NC-6300 and 1,2-diaminocyclohexane platinum (II) (oxaliplatin parent complex)-incorporating micelle NC-4016 (NCs) with that of epirubicin and oxaliplatin (E/O) in 44As3Luc cells using the combination index method. The in vivo antitumor activities of NCs and E/O were evaluated in mice bearing 44As3Luc xenografts. Pharmacokinetic analysis was performed by high-performance liquid chromatography and mass spectrometry. Cardiotoxicity of NC-6300 and epirubicin was assessed by echocardiography. Neurotoxicity of NC-4016 and oxaliplatin was evaluated by examining the paw withdrawal response to noxious mechanical stimuli. NCs showed a highly synergistic activity equivalent to E/O. In vivo, NCs exhibited higher antitumor activity in the subcutaneous tumor model and longer overall survival in the orthotopic tumor model than E/O (p < 0.001, p = 0.015, respectively). The intratumor concentrations of epirubicin and platinum were significantly higher following NCs than following E/O administration. Moreover, the micelles showed lower cardiotoxicity and neurotoxicity than the corresponding conventional drugs. The combined use of the micelles was associated with remarkable efficacy and favorable toxicities in the human gastric cancer model, and warrants the conduct of clinical trials.Combination chemotherapy is sometimes associated with serious adverse effects that lead to treatment cessation. The combined use of anticancer agent-incorporating polymeric micelles–which enable anticancer agents to exert potent antitumor effects while decreasing the toxicity of the drug payload–may overcome this drawback. Reports of combined use of micellar anti-cancer agents are scarce, however. The present study showed that the combination of epirubicin- and DACHP-incorporating polymeric micelles had a stronger antitumor effect and lower toxicity in gastric cancer xenografts than combined epirubicin and oxaliplatin. These results warrant the conduct of clinical trials of combination treatments with anticancer agent-incorporating micelles.